UFT with Irinotecan and Oxaliplatin for Metastatic Colorectal Cancer
Author Information
Author(s): Sheikh H Y, Valle J W, Waddell T, Palmer K, Wilson G, Sjursen A, Craven O, Swindell R, Saunders M P
Primary Institution: Christie Hospital, Manchester, UK
Hypothesis
Alternating oxaliplatin and irinotecan would allow patients to benefit from concurrent treatment with all three drugs as soon as they were diagnosed with metastatic disease.
Conclusion
UFT with LV plus alternating irinotecan and oxaliplatin is an effective, well-tolerated treatment approach for patients with metastatic colorectal cancer.
Supporting Evidence
- An objective response rate of 63% was observed in the evaluable patients.
- Median overall survival was 16.8 months.
- 67% of eligible patients received second-line therapy.
Takeaway
This study tested a new way to give cancer medicine to people with advanced colon cancer, and it worked well without causing too many side effects.
Methodology
This was a single-centre, open-label, non-randomised phase I/II study conducted on patients with histologically confirmed, metastatic adenocarcinoma of the colon or rectum.
Limitations
This was a single-centre, non-randomised study with a small patient number.
Participant Demographics
{"median_age":57,"age_range":"40-73","sex_distribution":{"male":25,"female":4},"performance_status":{"0":15,"1":11,"2":1}}
Statistical Information
Confidence Interval
{"overall_response_rate":"63% (95% CI: 49–80)","median_time_to_progression":"8.7 months (95% CI: 7.9–10.4)","median_overall_survival":"16.8 months (95% CI: 9.6–25.3)"}
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website